



December 7, 2018

Company name: SanBio Co., Ltd.  
 Representative: Keita Mori, Representative Director and President  
 (TSE Mothers Code: 4592)  
 Contact: Yoshihiro Kakutani, Corporate Officer of Management Administration  
 (TEL: +81-3-6264-3481)

## **Summary of Procurement of Funds in the Current Fiscal Year**

The Group (hereafter referring to both SanBio Co., Ltd. as “the Company,” and its subsidiary SanBio, Inc.) procured funds four times up to date in the current fiscal year (from February 1, 2018 to January 31, 2019).

The Group decided to allocate ¥2,000 million procured from entering a commitment line agreement with Mizuho Bank, Ltd. to establishing manufacturing, logistics, and sales systems for SB623 following its launch. As a result, the Group plans to spend a portion of ¥11,000 million raised through equity financing on R&D to expand indications of SB623 and introduce new drug substances. The overview of funds procured and their intended uses are outlined in the table below.

<Overview of funds procured in the current fiscal year (from February 1, 2018 to January 31, 2019)>

| Contracting party                    | Form of funding   | Amount of funds procured | Date of agreement (or date of approval) | Use of funds   |
|--------------------------------------|---|--------------------------|---|--|
| Mizuho Bank, Ltd.                    | Commitment line   | ¥2,000 million           | December 2018                           | <ul style="list-style-type: none"> <li>Establishment of manufacturing, logistics, and sales systems for SB623 following its launch</li> </ul>  |
| MUFG Bank, Ltd.                      | Commitment line   | ¥2,000 million           | November 2018                           | <ul style="list-style-type: none"> <li>Establishment of manufacturing, logistics, and sales systems for SB623 following its launch</li> </ul>  |
| Sumitomo Mitsui Banking Corporation. | Commitment line   | ¥1,000 million           | November 2018                           | <ul style="list-style-type: none"> <li>Establishment of manufacturing, logistics, and sales systems for SB623 following its launch</li> </ul>  |
|                                      | Equity finance (share acquisition rights with an exercise price adjustment clause by third-party allotment) | ¥11,000 million          |   | <ul style="list-style-type: none"> <li>Establishment of manufacturing, logistics, and sales systems for SB623 following its launch</li> <li>Development of programs targeting chronic motor deficit from ischemic stroke in Japan</li> </ul> |

|  |  |                           |  |  |
|--|--|---------------------------|--|--|
|  |  |                           |  | <ul style="list-style-type: none"> <li>• R&amp;D for expanding target regions to market SB623 in the future</li> </ul> |
|  |  | Total:<br>¥16,000 million |  |  |

<Overview of funds procured in the previous fiscal year (from February 1, 2017 to January 31, 2018)>

| Contracting party                                     | Form of funding | Amount of funds procured           | Date of agreement (or date of approval) | Use of funds   |
|---|-----------------|------------------------------------|---|--|
| MUFG Bank, Ltd. *1                                    | Borrowing       | ¥900 million                       | March 2017                              | <ul style="list-style-type: none"> <li>• Phase 2b clinical trial for the treatment of chronic motor deficit from ischemic stroke in the US</li> <li>• Phase 2 clinical trial for the treatment of chronic motor deficit from traumatic brain injury (TBI) in the US and Japan</li> </ul> |
| California Institute for Regenerative Medicine (CIRM) | Grant           | \$20 million<br>(¥2,200 million)*2 | June 2017                               | Phase 2b clinical trial for the treatment of chronic motor deficit from ischemic stroke in the US  |
| Mizuho Bank, Ltd.                                     | Commitment line | ¥1,600 million                     | August 2017                             | Cash in reserve for phase 2 clinical trial for the treatment of chronic motor deficit from TBI in the US and Japan   |
| MUFG Bank, Ltd. *1                                    | Commitment line | ¥500 million                       | October 2017                            | Cash in reserve for phase 2 clinical trial for the treatment of chronic motor deficit from TBI in the US and Japan   |
|   |                 | Total:<br>¥5,200 million           |   |  |

\*1: Due to functional realignment within the Mitsubishi UFJ Financial Group, the contracting party changed from Mitsubishi UFJ Trust and Banking Corporation to MUFG Bank, Ltd.

\*2: Exchange rate: \$1=¥110